{"id":"NCT02237950","sponsor":"Starpharma Pty Ltd","briefTitle":"Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)","officialTitle":"A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-13","primaryCompletion":"2016-12-09","completion":"2017-02-22","firstPosted":"2014-09-12","resultsPosted":"2019-07-09","lastUpdate":"2019-07-22"},"enrollment":586,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Bacterial Vaginosis"],"interventions":[{"type":"DRUG","name":"Metronidazole oral tablets 500mg","otherNames":[]},{"type":"DRUG","name":"1% SPL7013 Gel","otherNames":["VivaGel","astodimer sodium"]},{"type":"DRUG","name":"Placebo gel","otherNames":[]}],"arms":[{"label":"1% SPL7013 Gel","type":"EXPERIMENTAL"},{"label":"Placebo Gel","type":"PLACEBO_COMPARATOR"}],"summary":"A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.","primaryOutcome":{"measure":"Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings","timeFrame":"At or by the Week 16 visit","effectByArm":[{"arm":"1% SPL7013 Gel","deltaMin":130,"sd":null},{"arm":"Placebo Gel","deltaMin":158,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"16 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":45,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":294},"commonTop":["Vulvovaginal candidiasis","UTI","Headache","Vulvovaginal mycotic infection","Nasopharyngitis"]}}